The Impact of Clinical Pharmacist on the Intention of Hemodialysis Patients to Receive Pneumococcal Vaccination: Cross sectional study

Abstract

Objective: There is limited data on the coverage of the pneumococcal vaccine among dialysis patients. The role of pharmacists in increasing vaccine acceptance has become increasingly evident. However, studies evaluating the role of pharmacists in the acceptance of pneumococcal vaccines among dialysis patients are rare. This study aimed to assess the impact of a clinical pharmacist on the pneumococcal vaccination rate by delivering education and information to hemodialysis patients in hospitals. Methods: The study was conducted between October 2023 and May 2024 at the dialysis center of a state hospital. Participants were surveyed about pneumococcal disease and its vaccine, and afterwards, a pharmacist distributed an educational booklet on pneumococcal disease and its vaccine to provide training. Three months after the training, the patients' attitudes towards the pneumococcal vaccine and their vaccination status were evaluated, and the barriers affecting vaccination were identified. Results: The study found a significant lack of knowledge and awareness regarding pneumococcal disease and its vaccine among hemodialysis patients. The pharmacist-led educational intervention improved the participants' awareness and attitudes towards the disease and its vaccine (p<0.001), resulting in an increase in the pneumococcal vaccination rate (n=44; 29.3%). The biggest barrier to vaccination was found to be 'concern about side effects' (84; 79.2%). When comparing the demographic data of patients who were vaccinated and those who were not after the education, there was no statistically significant difference in age (p=0.639), gender (p=0.355), and monthly household income (p=0.111), while a statistically significant difference was observed in the education levels of the patients (p=0.015). Conclusion: The pneumococcal vaccination rate in hemodialysis patients has increased significantly due to the education provided by a clinical pharmacist in hospital settings.

Keywords

• Hemodialysis patients
• clinical pharmacist
• patient education
• pneumococcal vaccine
• vaccination rates

Supporting Institution

No specific funding was received

Ethical Statement

The study was approved by the Anadolu University Non-Interventional Clinical Trials Ethics Committee (No:595140, Approval date:27.09.2023). This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.

Thanks

I thank the doctors and nurses working in the hemodialysis unit for their support.

Klinik Eczacının Hemodiyaliz Hastalarının Pnömokok Aşısı Olma Niyetine Etkisi: Kesitsel çalışma

Abstract

Amaç: Diyaliz hastaları arasında pnömokok aşısının kapsamı hakkında sınırlı veri bulunmaktadır. Eczacıların aşı kabulünü artırmadaki rolü giderek daha belirgin hale gelmiştir. Ancak, diyaliz hastaları arasında pnömokok aşılarının kabulünde eczacıların rolünü değerlendiren çalışmalar nadirdir. Bu çalışma, hastanelerde hemodiyaliz hastalarına eğitim ve bilgi vererek klinik eczacının pnömokok aşısı ile aşılanma oranı üzerindeki etkisini değerlendirmeyi amaçlamaktadır. Yöntemler: Çalışma, Ekim 2023 ile Mayıs 2024 tarihleri arasında bir devlet hastanesinin diyaliz merkezinde gerçekleştirildi. Katılımcılara pnömokok hastalığı ve aşısı hakkında anket yapıldı ve sonrasında klinik eczacı tarafından, pnömokok hastalığı ve aşısı hakkında bilgilendirme broşürü dağıtılarak eğitim verildi. Eğitimden üç ay sonra, hastaların pnömokok aşısına yönelik tutumları ve aşılanma durumları değerlendirildi ve aşılamayı etkileyen engeller belirlendi. Bulgular: Çalışma, hemodiyaliz hastaları arasında pnömokok hastalığı ve aşısı hakkında önemli bir bilgi ve farkındalık eksikliği buldu. Eczacı liderliğindeki eğitim müdahalesi, katılımcıların hastalık ve aşıya yönelik farkındalık ve tutumlarını iyileştirdi (p<0,001), bu da pnömokok aşılanma oranında artışa yol açtı (n=44; %29,3). Aşılanma durumunun en büyük engeli 'yan etkiler konusunda endişe' olarak belirlendi (84; %79,2). Eğitimden sonra aşılanan ve aşılanmayan hastaların demografik verileri karşılaştırıldığında, yaş (p=0,639), cinsiyet (p=0,355) ve aylık hane geliri (p=0,111) açısından istatistiksel olarak anlamlı bir fark bulunmazken, hastaların eğitim seviyelerinde istatistiksel olarak anlamlı bir fark gözlemlenmiştir (p=0,015). Sonuç: Hemodiyaliz hastalarında pnömokok aşısı ile aşılanma oranı, hastane ortamında klinik eczacı tarafından sağlanan eğitim sayesinde önemli ölçüde artmıştır.

Keywords

• Hemodiyaliz hastaları
• klinik eczacı
• hasta eğitimi
• pnömokok aşısı

Supporting Institution

Belirli bir finansman alınmadı

Ethical Statement

Çalışma, Anadolu Üniversitesi Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu tarafından onaylanmıştır (No:595140, Onay tarihi:27.09.2023). Bu çalışma Helsinki Deklarasyonu'na uygun olarak gerçekleştirilmiştir. Tüm katılımcılardan yazılı bilgilendirilmiş onam alınmıştır.

Thanks

Hemodiyaliz servisinde çalışan hekim ve hemşirelere desteklerinden dolayı teşekkür ederim.

References

1. 1. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302:1782–9.
2. 2. Viasus D, Garcia-Vidal C, Cruzado JM, et al. Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrol Dial Transplant. 2011;26:2899–906.
3. 3. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end- stage renal disease. Chest. 2001;120:1883–7.
4. 4. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70:1135–41.
5. 5. Andrassy KM. Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kid-ney disease’. Kidney Int. 2013;84(3):622–3.
6. 6. Haddiya I. Current Knowledge of Vaccinations in Chronic Kidney Disease Patients. Int J Nephrol Renovasc Dis. 2020;13:179-185.
7. 7. T.C. Sağlık Bakanlığı. Genişletilmiş Bağışıklama Programı Genelgesi. Erişim Tarihi: 19 Aralık 2024. https://www.saglik.gov.tr/TR,11137/genisletilmis-bagisiklama-programi-genelgesi-2009.html
8. 8. Huang M, Yang HK, Zhang D. Pneumococcal vaccination coverage in immunocompromised adults in the United States. Value in Health. 2014;17(3):A277.

9. 9. Bond TC, Patel PR, Krisher J, et al. Association of standing-order policies with vaccination rates in dialysis clinics: a US-based cross- sectional study. Am J Kidney Dis. 2009;54(1):86-94.
10. 10. Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis. 2012;60(6):959-965.
11. 11. Kara S, Torun D, Oruç E, Habeşoğlu MA, Akçay MŞ. Pneumococcal and influenza vaccines in dialysis patients: Vaccination information, rates and patient awareness. Turk J Nephrol. 2021.21136
12. 12. Yazıcı R, Güney İ, Yürekli A, Can S. Awareness and rates of vaccination in hemodialysis patients. J Med Palliat Care. 2023;4(4):283-287.
13. 13. Mutlu A, Şengül E, Boz G. A cross-sectional survey study on influenza and pneumococcal vaccination rates and the factors affecting vaccination rates in hemodialysis patients in Kocaeli Province of Turkey. Ther Apher Dial. 2022;26(3):640-648.
14. 14. Wehbi NK, Wani RJ, Klepser DG, Murry J, Khan AS. Impact of implementing a technology platform in community pharmacies to increase adult immunizations rates. Vaccine. 2019;37(1):56–60.
15. 15. Klassing HM, Ruisinger JF, Prohaska ES, Melton BL. Evaluation of pharmacist-initiated interventions on vaccination rates in patients with asthma or COPD. J Community Health. 2018;43(2):297–303.
16. 16. Otsuka SH, Tayal NH, Porter K, Embi PJ, Beatty SJ. Improving herpes zoster vaccination rates through use of a clinical pharmacist and a personal health record. Am J Med. 2013;126(9):832 e1–6.
17. 17. Centers for Disease Control and Prevention. Global pneumococcal disease and vaccine. Erişim Tarihi: 19 Aralık 2024. https://www.cdc.gov/pneumococcal/global.html
18. 18. Signorell, A. DescTools: Tools for descriptive statistics. 2023.
19. 19. Tan HZ, Phang CC, Wu SY, et al. Improving influenza and pneumococcal vaccination uptake among incident peritoneal dialysis patients: a quality improvement initiative. Int Urol Nephrol. 2021;53(10):2167-2175.
20. 20. Topbaş E, Turan BB, Bay H, Emir AH, Çıtlak U, Erdoğan TK. Use of Regular Vaccination Schedule in Hemodialysis Patients and Awareness. Nefroloji Hemşireliği Derg. 2020; 15 (1): 10-15.
21. 21. Günay E, Kaya S ̧, Yüksel E. The blind spot on hemodialysis: vaccination. Turk Hij Den Biyol Derg. 2020;77(2):149–54.
22. 22. Duval L, George C, Hedrick N, Woodruff S, Kleinpeter MA. Network 13 partnership to improve the influenza, pneumococcal pneumonia, and hepatitis B vaccination rates among dialysis patients. Adv Perit Dial. 2011; 27:106–11.
23. 23. Ozdemir N, Aktas BY, Gulmez A, Ink, et al. Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study. Support Care Cancer. 2023;31(3):194.
24. 24. Tyler R, Kile S, Strain O, Kennedy CA, Foster KT. Impact of pharmacist intervention on completion of recombinant zoster vaccine series in a community pharmacy. J Am Pharm Assoc. 2021;61(4S):S12–S16.
25. 25. Page A, Harrison A, Nadpara P, Goode JR. Pharmacist impact on pneumococcal polysaccharide vaccination rates in patients with diabetes in a national grocery chain pharmacy. J Am Pharm Assoc. 2020;60(3S):S51-S5 e1.
26. 26. Abu-Rish EY, Barakat NA. The impact of pharmacist-led educational intervention on pneumococcal vaccine awareness and acceptance among elderly in Jordan. Hum Vaccin Immunother. 2021;17(4):1181–1189.
27. 27. Pizzi LT, Prioli KM, Fields Harris L, et al. Knowledge, activation, and costs of the Pharmacists’ Pneumonia Prevention Program (PPPP): a novel senior center model to promote vaccination. Ann Pharmacother. 2018; 52(5):446–453.
28. 28. Brackett A, Butler M, Chapman L. Using motivational interviewing in the community pharmacy to increase adult immunization readiness: a pilot evaluation. J Am Pharm Assoc. 2015;55(2):182–186.
29. 29. Akinbodewa AA, Gbadegesin BA, Adejumo OA, et al. A multicentre study of awareness and practice of vaccination against infectious diseases among haemodialysis subjects in Nigeria. West Afr J Med. 2019;36(3):239-245.
30. 30. Wong-Beringer A, Brodetsky E, Quist R. Pneumococcal vaccination in hospitalized elderly patients: role of the pharmacist. Pharmacotherapy. 2003;23(2):199–208.
31. 31. National Vaccine Advisory Committee (2012) A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011. Public Health Rep 127:1–42.
32. 32. Glatman-Freedman A, Nichols K. The effect of social determinants on immunization programs. Hum Vaccin Immunother. 2012;8(3):293–301.